| References: |
Description of Tacedinaline: Tacedinaline, also known as CI-944, is an orally bioavailable substituted benzamide derivative with potential antineoplastic activity. Tacedinaline inhibits histone deacetylation, which may result in histone hyperacetylation, followed by the induction of differentiation, the inhibition of cell proliferation, and apoptosis in susceptible tumor cell populations. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
For the detailed information about the solubility of CI994 (Tacedinaline) in water, the solubility of CI994 (Tacedinaline) in DMSO, the solubility of CI994 (Tacedinaline) in PBS buffer, the animal experiment（test） of CI994 (Tacedinaline), the in vivo,in vitro and clinical trial test of CI994 (Tacedinaline), the cell experiment（test） of CI994 (Tacedinaline), the IC50, EC50 and Affinity of CI994 (Tacedinaline) , please contact DC Chemicals. |
